IA
MRTX

IndexIQ Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

IndexIQ Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$42K Buy
+515
New +$52.7K ﹤0.01% 1145

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

IndexIQ Advisors's MRTX Position: Q1 2022 in Review

IndexIQ Advisors opened a new position in Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2022: 515 shares worth $42K. The stake represents ﹤0.01% of the portfolio and ranks #1145 among its holdings.

253 funds tracked by Wall St. Rank hold MRTX as of Q1 2022.

  • IndexIQ Advisors held 515 shares of Mirati Therapeutics, Inc. Common Stock worth $42K as of Q1 2022.
  • Mirati Therapeutics, Inc. Common Stock was a new IndexIQ Advisors position in Q1 2022.
  • Mirati Therapeutics, Inc. Common Stock made up ﹤0.01% of IndexIQ Advisors's portfolio in Q1 2022, its #1145 holding.
  • 253 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.